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 ABSTRACT 
Glioblastoma is the most common and malignant form of brain cancer, for which the standard treatment 
is maximal surgical resection, radiotherapy and chemotherapy. Despite these interventions, mean overall 
survival remains less than 15 months, during which extensive tumor infiltration throughout the brain 
occurs. The resulting metastasized cells in the brain are characterized by chemotherapy resistance and 
extensive intratumoral heterogeneity. An orthogonal approach attacking both intracellular resistance 
mechanisms as well as intercellular heterogeneity is necessary to halt tumor progression. For this reason, 
we established the WINDOW Consortium (Window for Improvement for Newly Diagnosed patients by 
Overcoming disease Worsening), in which we are establishing a strategy for rational selection and 
development of effective therapies against glioblastoma. Here, we overview the many challenges posed 
in treating glioblastoma, including selection of drug combinations that prevent therapy resistance, the 
need for drugs that have improved blood brain barrier penetration and strategies to counter 
heterogeneous cell populations within patients. Together, this forms the backbone of our strategy to 
attack glioblastoma.  
 
BACKGROUND AND CHALLENGES 
 
Classification of glioblastoma and inter-patient heterogeneity 
Gliomas are the most common malignancies of the central nervous system (CNS). Most glioblastomas 
(GBMs) arise de novo without any sign of a less malignant precursor (Ohgaki and Kleihues, 2013). Primary 
GBMs typically occur at an average age of 62 years, rapidly progress and have an extremely poor prognosis. 
However, 10% of GBMs progress from low-grade diffuse astrocytomas or anaplastic astrocytomas (Figure 
1A). These “secondary” GBMs occur at an average age of 45 years and offer a slightly better prognosis than 
primary lesions. According to the WHO 2016 classification, gliomas are defined based on mutations in the 
IDH1 gene with/without chromosomal 19q loss (summarized in Figure 1B, taken from Verhaak 2016). 
Astrocytic gliomas are classified based on histologic criteria from lower grade lesions (grades II–III) to high-
grade (grade IV) malignancies (WHO 2016; previous classifications given in Louis et al, 2010; Zhu and 
Parada, 2002; Weller et al, 2005). Originally, the Cancer Genome Atlas Network (TCGA, Verhaak et al, 2010) 
defined molecular signatures within GBM (grade IV), which were distinguishable based on expression of 
lineage markers. These subgroups are termed “classical”, “mesenchymal”, “proneural” and “neural”, 
although existence of the latter group is debated (Sideway 2017). The proneural subtype correlates with 
better prognosis whereas the mesenchymal and classical subtypes correspond to poor prognosis (Lin et al, 
2014). These quantitative relationships, based on WHO criteria, molecular features and histology are 
summarized in Figure 1. 
 
 Figure 1. (A) Circos plot showing the histological classification system as used in the clinic until recently. (B) 
Sankey plot showing the quantitative relation of different adult gliomas (based on 1,122 patients in the 
TCGA database www.cbioportal.org, see also Carelli et al 2016 and Weller et al 2017), grouped by the WHO 
2016 classification (IDH mutated; IDH/ATRX comutated;1p19q codeletion); molecular profile (Mesenchymal, 
Classic like, LGm6-GBM_PA [LGGs in the third methylation cluster of IDH-wild type tumours as pilocytic 
astrocytoma-like], GCIMP; and histological class: astrocytoma (AS), oligodendroglioma (OD) and 
glioblastoma (GBM). (C) Current treatment of GBM after maximal safe surgical resection. After surgery, RT 
is continued for 6 weeks combined with TMZ treatment. Subsequently, adjuvant TMZ five days per week is 
indicated for at least six months. po, per os (oral administration).  
 
Current clinical trials are not focused on GBM driver mutations 
A                                                   B
C
WHO 2016 HistologyMolecular profileTumor type
Diffuse 
glioma
The standard treatment of GBM is based on the international EORTC-study (Stupp et al. 2005), consisting of 
maximal safe surgical resection, followed by six weeks of radiotherapy (RT) and concomitant Temozolomide 
(TMZ) chemotherapy with subsequent adjuvant TMZ chemotherapy for six months, Figure 1C. Compared to 
RT alone, with a median survival time of 12.1 months, the combination of RT plus TMZ increases median 
overall survival time (OS) by 2.5 months to 14.6 months (Weller et al, 2016; Stupp et al, 2009; 2005). A 
group of patients displaying silencing of the MGMT-gene promoter via DNA methylation, have repressed 
DNA damage repair and is therefore more sensitive to the alkylating effect of TMZ (Hegi et al, 2005). In 
clinical practice, TMZ is administered regardless of the patient’s promoter methylation status.  
Many efforts are underway to improve the outcome of the current standard therapy, attacking 
driver as well as non-driver targeted therapies (graphically summarized in Figure 2A). Currently, there are 
more than 225 ongoing trials in GBM, of which over 60% include systemic therapy, comprising 
chemotherapy/DNA damaging compounds (23%), immunotherapy (13%), VEGF targeted therapy (8%) and 
PI3K targeted therapy (3%), shown in Sankey plot in Figure 2B.  
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Figure 2. Driver versus non-driver focussed therapies against GBM in clinical trials (ClinicalTrials.gov). (A) 
Circos plots showing non-driver targets and driver targets of currently applied clinical trials against GBM. 
Cellular location of targets is shown as extracellular, membrane bound or intracellular. Non-driver genes are 
classified into immune targets, receptors and receptor ligands; and cytotoxic/DNA damaging targets. The 
driver mutation circos plot is divided in targetable mutations, absence of druggable mutations and non-
druggable driver mutations. (B) Sankey plot showing the quantitative relation of the number of trials 
towards each target in ongoing clinical trials. Non-driver targets (upper portion) as well as driver targets 
using FDA approved mutation specific small molecules (lower portion) are shown. Note that almost no 
approaches to driver targets are currently in clinical trials. Abbreviations: RTK, receptor tyrosine kinase; 
SMO, smoothened Shh receptor; Ptc, Patched Shh receptor; TGF Transforming growth factor beta; HGF, 
Hepatocyte growth factor; CRM1, chromosome region maintenance 1; COX2, Cyclooxygenase 2; PD1, 
Programmed cell death protein 1; EGFR, Epidermal growth factor receptor, ATRX, Alpha 
Thalassemia/Mental Retardation Syndrome X-Linked gene; RB1, retinoblastoma 1 protein; TP53,  tumour 
protein p53; p15/CDK2NB, cyclin-dependent kinase inhibitor 2B; IDH1 Isocitrate dehydrogenase homolog 1; 
NF1, Neurofibromatosis type 1; PIK3R1 Phosphatidylinositol 3-kinase regulatory subunit alpha; PIK3CA, 
Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha; PDGFRA, Platelet-derived growth 
factor receptor A; MDM2, Murine double minute 2; PTEN, Phosphatase and tensin homolog; p16/CDK2NA, 
cyclin-dependent kinase inhibitor 2A; CDK4, cyclin dependent kinase 4.  
 
Although 70% of GBMs contain tumor driver mutations that are targetable by therapy (Figure 2, Carelli et 
al, 2016), in current clinical trials there is no focus on these driver mutations, except for EGFR- targeted 
therapy (11% of clinical trials, Figure 2B).Trials aimed at driver-mutations have been largely unsuccessful 
(for instance NCT00187486, NCT0062243 and NCT00671970 aimed at EGFR inhibition), possibly because of 
poor penetrance of drugs into the CNS through the blood brain barrier [BBB; (Oberoi et al, 2013; Tang et al, 
2012; Porta et al, 2011)].  
Here, we address the challenges associated with the efficient treatment of GBM though 
combination therapy. We see these as: (1) identification of drugs that have desired BBB penetration, (2) 
addressing whether combination-therapies are of benefit in targeting intratumoral heterogeneity and (3) 
overcoming drug resistance. Based on this landscape, we outline the strategy adopted by the WINDOW 
consortium for the selection and further development of effective therapies against GBM. 
 
Challenge 1: The BBB and perivascular/perineural microinvasion – The BBB is the natural barrier that 
prevents toxins from reaching the brain. It is a major obstacle to brain tumor therapy, preventing the 
delivery of most chemotherapeutic and targeted agents to the tumor location (e.g. Sminia and Westerman 
2016; van Tellingen et al, 2015). Since most drugs have been developed for applications outside the brain 
and therefore selected for low BBB penetration to avoid neurotoxicity, most FDA approved drugs have poor 
target engagement in the brain.  
Gliomas show perivascular and perineural microinvasion (Cuddapah et al, 2014; Gritsenko et al, 
2012; Montana et al, 2011; Farin, et al, 2006). Glioma tumor cells can form multicellular networks 
connected through branched filamentous protrusions connecting cells, or epithelial-like linear adherent 
junctions between directly adjacent cells (Friedl et al, personal communication). Therefore, individual 
tumor cells are localized distantly from the bulk of the tumor (Sherriff et al, 2013) and might be more 
difficult to reach both therapeutically as well as surgically.  
For many years, different strategies have been investigated to facilitate BBB penetration by 
chemotherapeutics, reviewed in Upadhyay, 2014 and Lu et al, 2014. These include the use of 1) non-
invasive techniques, such as radiotherapy (Trnovec et al, 2016), ultrasound and microbubbles 
(Lamanauskas et al, 2013; Escoffre et al, 2013; Rachlin et al, 2013; Chu et al, 2016), and biological 
approaches via cell penetrating peptides and viral vectors (Sidaway, 2018); 2) invasive techniques, such as 
convection enhanced delivery (reviewed by Vogelbaum and Aghi, 2015), and 3) alternative routes such as 
intranasal application, bypassing the cardiovascular system (reviewed by Peterson et al, 2014).  
The high prevalence of brain metastasis from the lung, breast and melanoma, makes it attractive to 
develop compounds that target driver mutations specific for these tumor types, leading to the 
development of potent kinase inhibitors that do cross the BBB. These include compounds targeting driver 
mutations such as Osimertinib (targeting EGFR T790M) and Lorlatinib (targeting ALK mutations), as well as 
the radio-sensitizing drug AZD0156 (ATM) and the PI3K/AKT/mTOR pathway inhibitor GDC-0084. GBM is 
rarely the main therapeutic focus, due to its relatively small market size. However, because drug discovery 
is a long-term endeavour and an extremely expensive one (estimated that a single drug can take over 10 
years and cost more than £500M to develop) (Austin, 2017), drug repurposing (i.e. the identification of new 
therapeutic uses for existing drugs), is the only route currently available as a solution to this challenge. To 
date, there has been no systematic evaluation of the already available approved drugs against GBM.  
 
Challenge 2: Drug resistance and intratumoral molecular heterogeneity 
GBM is characterized by intratumoral heterogeneity in which subpopulations of cells have distinct features, 
largely consisting of  (1) gene copy number variations as shown for PTEN, TP53 and MDM4 (Sottoriva et al, 
2013; Johnson et al, 2014; Meyer et al 2015), (2) clonal ploidy differences (Stieber et al, 2014; Johnson et al. 
2014; Meyer et al, 2015), (3) extrachromosomal DNA elements (deCarvalho et al, 2018; Turner et al, 2017), 
(4) signalling heterogeneity as a result of mosaic receptor tyrosine kinase activity (Snuderl et al, 2011; Little 
et al. 2012; Szerlip et al. 2012) including structural variants of EGF receptor (Francis et al, 2014; Meyer et al, 
2015), and (5) lineage heterogeneity, i.e. GBM cells express markers of lineage derivatives of 
stem/progenitor cells such as proneural, neural as well as astroglial genes (Verhaak et al, 2010; Phillips et 
al, 2006; Al-Mayhani et al, 2011; Sottoriva et al. 2013; Patel et al, 2014; Kenney-Herbert et al, 2015; 
Piccirillo et al, 2015a; Piccirillo et al, 2015b; Wang et al, 2016, Meyer et al, 2015). The different forms of 
cellular heterogeneity are summarized in Figure 3A.  
The sensitivity of individual tumors towards drugs can vary due to intrinsic resistance which is pre-
existing or acquired as a result of drug therapy (Sequist et al, 2011; Garrett et al, 2011; Prahallad et al, 
2012; Wilson et al, 2012). Drug resistance, intrinsic or acquired, is affected by intratumoral heterogeneity 
due to genetic or phenotypic heterogeneity (the mechanisms are listed in Figure 3B). Preclinically, 
intratumoral subpopulations display a differential response to therapeutics (Meyer et al, 2015; Hägerstrand 
et al, 2011; Heo et al, 2014; Saito et al, 2014; Lee et al, 2017; Lan et al, 2017). Moreover, a re-transplanted 
tumor seems to retain its intrinsic resistance, indicating that there is a population with a long term tumor 
initiation or drug resistance potential (Lan et al, 2017). These studies implicate intrinsic cell populations in 
each GBM patient exhibiting pre-existing resistance to therapy (Meyer et al, 2015). In the clinic, radiation 
resistance is observed frequently in relapsed GBMs (Hochberg and Pruitt, 1980; Kelley et al, 2016; 
Fidoamore et al, 2016). Several alternative mechanisms have been found to underlie therapy resistance. 
For instance, EGFR inhibitor resistance may occur as a consequence of loss of extrachromosomal mutant 
EGFR DNA, promyelocytic leukemia (PML) gene expression, PTEN phosphorylation status, PDGFR 
upregulation, ERBB4 activation, AMPK levels or IL-6 upregulation (Nathanson et al, 2013; O’Rourke et al, 
2017; Iwanami et al, 2013; Fenton et al, 2012; Akhavan et al, 2013; Donoghue et al, 2018; Guo et al, 2009; 
Zanca et al, 2017). 
Figure 3. Resistance and heterogeneity mechanisms of GBM. (A) Circos plot showing different molecular 
mechanisms underlying the generation of cellular heterogeneity; (B) Sankey plot quantitatively summarising 
the causes of heterogeneity and drug resistance involving driver targets in GBM. Targets that are frequently 
mutated are shown in color. PML, promyelocytic leukemia; AMPK, 5' adenosine monophosphate-activated 
protein kinase; MAPK, Mitogen Activated Protein Kinase. 
 
Challenge 3 Combination therapies against heterogeneous populations 
Since intratumoral heterogeneity and drug resistance can occur simultaneously, a promising approach 
might be to combine targeted drugs that hit several survival mechanisms at once for different cell 
populations. This could provide a synergistic (i.e. more than additive) effect and prevent therapy-
resistance. However, identification of these synergistic combinations has thus far only been possible in an 
empirical setting (by experimentally testing all combinations). A major challenge is therefore to match GBM 
vulnerabilities to effective drug combinations. 
A                                                        B Gene/groups of genes Mechanism Result
Tumors are dependent on a limited number of molecular mechanisms for their survival and 
proliferation (Hanahan and Weinberg, 2011; Wang et al, 2015). Combination therapy enables simultaneous 
targeting of these crucial mechanisms. In addition, for personalized cancer treatment, a focus on 
drug/irradiation or drug/drug combinations is particularly appealing since enhanced efficacy can be 
assessed for each radiation-dose or drug-concentration window.  
Strategies for selecting synergistic and effective drug combinations (Dancey and Chen, 2006; Day 
and Siu, 2016) can be based on several precepts, including: (1) maximal target inhibition, achieved by 
synergistic drug combinations that hit the same target, especially important in the case of oncogene 
addiction. Drug resistance might also be avoided by this approach as well as other novel approaches (Bar-
zeev et al, 2017; Li et al,2016; Zhitomirsky et al, 2016); (2) maximal pathway inhibition. In a similar manner, 
maximal pathway inhibition can be used to suppress an entire pathway by inhibiting it at multiple levels. An 
example of this strategy is the FDA approved combination of the BRAF inhibitor vemurafenib and the MEK 
inhibitor cobimetinib in BRAFV600 mutated melanoma which results in maximal pathway inhibition in cases 
where the tumor is dependent on the BRAFV600 mutation (Larkin et al, 2014). Also, within GBM 
radiotherapy and PARP-inhibition have shown synergy (Lesueur et al, 2018); (3) feedback inhibition 
between and within pathways. In many cases this affects upstream pathway activation through 
downstream targets of the initial inhibited pathway (Sun and Hobor et al, 2014; Sun and Wang et al, 2014; 
Rozengurt et al, 2014); and finally (4) synthetic lethality (feed forward) inhibition, in many cases affecting 
inhibition of two parallel pathways downstream of activated oncogenes (Croesmann et al, 2018). For 
feedback inhibition and synthetic lethality approaches, information on underlying therapy-resistance is 
scarce, and direct targets are difficult to identify, rendering the rational design of pathway combinations 
difficult. 
 
AIMS OF THE WINDOW CONSORTIUM 
General aims of the consortium 
Within the WINDOW consortium, our aim is to provide a solution to these challenges by examining the links 
between intratumor molecular heterogeneity, prediction of in vitro therapeutic drug combination and 
testing, as well as emerging clinical data, areas which must be addressed for successful development of 
effective therapeutics. Our overall objective is to create a validated patient-centred platform based upon 
integration of patient-derived cell systems, detailed genetic analysis of tumor cell population, together with 
their treatment with the most effective combination therapies. At a more immediate level, we will develop 
a collaborative pipeline to enable patient-stratified treatments with the most effective combinations of 
FDA approved drugs, thereby offering a Window for Improvement for Newly Diagnosed patients thereby 
Overcoming Disease Worsening (WINDOW). 
 
WINDOW specific aim 1: Repurposing of clinically approved drugs 
To be able to repurpose FDA approved drugs against GBM, drugs must combine traditional qualities, such 
as optimal systemic absorption, distribution, metabolism, and excretion (ADME), with enhanced CNS 
bioavailability. Selection criteria are therefore: (1) molecular mode of action [i.e. target specificity], (2) 
experimental proof of efficacy, (3) ADME characteristics, (4) documented CNS penetrance and (5) 
toxicology including the absence of neural side-effects.  
Most FDA approved drugs will never reach the brain because they were selected based on inability 
to cross the blood brain barrier. In addition, most drugs are substrates for efflux pumps and are actively 
pumped out of the brain through ABC transporters such as P-gp and ABCG2. Recent development of drugs 
against metastasized from the lung, skin and breast tumors have provided important information how to 
design drugs that have optimal characteristics to reach the brain tumor. Primary brain tumor have suffered 
from a lack of clinically relevant drugs targeting brain specific lesions. Nevertheless, we show here how to 
use data from non-primary brain tumor fields to select drugs that might be lead drugs for application 
against brain tumors. A first step in this process has been to curate GBM drug information in a form that is 
readily accessible to all preclinical GBM researchers. This has now been achieved through the 
establishment of the GBM Drug Bank (www.gbmdrugbank.com; Svensson et al 2018). This resource 
includes all FDA approved drugs suitable for repurposing that are active in GBM preclinical models.  
 
WINDOW specific aim 2: Overcoming drug resistance through combination therapies 
In the WINDOW project, we have developed a novel strategy to identify effective drug-combinations using 
a topology-based approach which we call the drug-atlas (Narayan et al, submitted). This atlas is built from 
drug-response encyclopedias and can be considered as a framework of therapeutic action and therefore 
can be interpreted as a drug-vulnerability landscape of cancer. The methodology is based on the finding 
that most tumors contain multiple independent survival/proliferation mechanisms. This novel rational and 
generalizable strategy opens the door to unforeseen personalized multi-drug combination approaches.  
Some of the drug combinations identified with the drug atlas will show a lack of response in a 
number of cell lines. For this we will apply CRISPR/CAS9 technologies to elucidate the molecular basis for 
the lack of therapeutic response (Tzelepis et al, 2016). We will (1) identify genetic vulnerabilities of these 
clonally derived cell lines and to determine the mechanisms that are responsible for the lack of response 
therapy. Clonally derived glioblastoma cell lines that show drug resistance are infected with a CRISPR knock 
out library.  Subsequently, next gen sequencing of the CRISPR cassettes will reveal which CRISPR constructs 
are lost upon exposure to the combination therapy and hence identify the genes responsible for the 
sensitization to the drug combination. This drop out screen methodology will reveal the sensitivities of the 
drug resistant cell lines, which will differ from the control cell line. Finally, drugs can be chosen that hit the 
identified protein or process as directly as possible. In addition, drug resistance mechanisms to 
monotherapy or combination therapy can be identified using CRISPR screening technologies. 
Two major limitations of combination therapy with targeted drugs are the narrow time window 
wherein drugs can or need to be delivered, and the narrow therapeutic window between enhanced tumor 
kill and toxicity. Examples of drug combination-induced toxicities are shown in Table 1.  
 
Table 1 
Examples of accumulating toxicities 
Challenge Drug combination 
Tumour 
type 
Clinical 
phase 
Outcome Reference 
Target 
engagement & 
PK/PD 
Sirolimus + erlotinib GBM Phase II 
No improvement over 
control 
Reardon et al, 
2010 
  
Cetuximab or 
panitumumab to 
bevacizumab and 
chemotherapy  
Colon Phase III 
No improvement over 
control 
Hecht et al, 2009; 
Tol et al, 2009 
Toxicity 
Bevacizumab, 
irinotecan, 
temozolomide 
GBM Phase II Hematological toxicity Peters et al, 2015 
  
Bevacizumab (VEGF 
inhibitor), 
temozolomide 
GBM 
Phase II 
 
Blood pressure, 
Hematological toxicity 
Reyes Botero et al, 
2018 
  
Onartuzumab (c-
MET) 
GBM Phase II 
Peripheral edema, 
Asthenia 
 
bevacizumab (VEGF 
inhibitor) 
  
Bevacizumab (VEGF 
inhibitor) + sunitinib 
Renal cell 
carcinoma 
Phase I 
Vascular/hematological 
toxicities  
Feldman et al, 
2009* 
  
Temsirolimus 
(mTOR inhibitor) + 
sunitinib 
Renal cell 
carcinoma 
Phase I 
Skin/hematological 
toxicities 
Patel et al, 2009* 
  
Everolimus 
(MTORC1) 
combined with 
exemestane 
Breast 
cancer 
Phase III 
Stomatitis, intestinal, 
hematological toxicities 
Baselga et al, 2012 
  
MEK inhibitor 
combined with AKT 
inhibitor  
Various Phase II Intestinal, skin Tolcher et al, 2015 
  
Ipilimumab 
combined with 
nivolumab  
Melanoma Phase III Intestinal, skin Larkin et al, 2015 
 
BRAF inhibition 
combined with MEK 
inhibition  
Melanoma Phase II Fever 
Flaherty et al, 
2012 
*Taken from Day and Siu Genome Medicine (2016) 8:115 
 
Additive toxicities can be avoided by using drug combinations that have different toxicity patterns. For 
example, in the combination with irradiation, the crucial issue is the scheduling and administration of 
targeted and radiosensitizing agents. To predict possible toxicities, we will generate a Toxicity Atlas, to 
enable selection of drug-combinations with complementary toxicities and prevent accumulated side 
effects. 
 
Future Perspectives  
By using our WINDOW consortium approach, we aim to overcome issues that currently prevent an effective 
therapeutic strategy against GBM. These issues concern intratumoral heterogeneity and identification of 
more effective therapies targeting the heterogeneous tumor populations characteristic of GBM, initially 
focussing on the repurposing of FDA-approved small molecule drugs. Recognizing the fact that many of the 
current set of FDA-approved drugs were developed with non-CNS penetrance as an objective, the 
WINDOW program has the longer-term aim of re-developing approved drugs that show efficacy in 
preclinical models, through industry-proven lead optimization approaches. 
Based on the high prevalence of brain metastases from lung cancer, breast cancer and melanoma, 
industry research is leading to the development of kinase inhibitors for treating brain metastases of other 
solid tumors, including driver-targeted compounds such as Osimertinib, AZD3759, NT113, Lorlatinib, GDC-
0084, as well as the radio-sensitizing drug AZD0156. An additional focus could be on inhibitors showing 
polypharmacology (Knight et al., 2010), in which either a single drug or a combination of drugs can restrict 
or even gridlock adaption mechanisms of the tumor. 
Many of these new approaches could be tested in preclinical models recapitulating the inter- as 
well as intra-patient heterogeneity to enable further dissection of the molecular basis of resistance 
development in the context of the host-tumor interaction, as well as direct tumor toxicity. A better 
mechanistic understanding of the toxicity of drug combinations and/or drug polypharmacology will assist in 
prioritizing candidate therapies. Moreover, activation of the immune system might further enhance the 
effects of our strategy. The objective of the WINDOW Consortium is to combine these paradigms, to deliver 
new and effective therapeutic strategies for GBM. 
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